Research programme - small molecule therapeutics - Takeda/Numerate

Drug Profile

Research programme - small molecule therapeutics - Takeda/Numerate

Latest Information Update: 22 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Numerate; Takeda
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; CNS disorders; Gastrointestinal disorders

Most Recent Events

  • 12 Jun 2017 Takeda Pharmaceutical and Numerate enter into an agreement to discover and develop small molecule therapeutics for the treatment of Gastrointestinal disorders, CNS disorders and Cancer
  • 12 Jun 2017 Early research in Cancer in USA (unspecified route)
  • 12 Jun 2017 Early research in CNS disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top